People · Operator
Named in public records as an officer, director or promoter · active 2017–2025 · Healthtech, Other Health Care, Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Acutus Medical, Inc. | — | Healthtech | Series D+ | $296.3M | $69.0M | 2022 |
| Conventus Orthopaedics Inc | — | Other Health Care | Series C | $144.2M | $921.2M | 2018 |
| Adela, Inc. | — | Biotechnology | Series C | $108.5M | $156.3M | 2021 |
| Aurion Biotech, Inc. | — | Biotechnology | Series C | $81.3M | $1.2B | 2022 |
| InCarda Therapeutics, Inc. | — | Pharmaceuticals | Series B | $66.3M | $857.5M | 2017 |
| Farapulse, Inc. | — | Biotechnology | Series A | $36.3M | $433.8M | 2018 |
| Nxt Biomedical, Llc | — | Other Health Care | Series A | $19.4M | $187.6M | 2018 |
Andrew ElBardissi at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Andrew ElBardissi on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Weisskoff | 2 | 12 |
| Steven Hochberg | 2 | 9 |
| David Bonita | 2 | 6 |
| Shaden Marzouk | 2 | 2 |
| Kevin Johnson | 1 | 12 |
| Paul Brown | 1 | 12 |
| Paul Buckman | 1 | 10 |
| Isaac Cheng | 1 | 9 |
| Scott Huennekens | 1 | 7 |
| Alan Colowick | 1 | 7 |
| J. Daniel Cole | 1 | 7 |
| James Eadie | 1 | 6 |
| David Scheer | 1 | 6 |
| Robert A Kukuljan | 1 | 6 |
| David Blue | 1 | 5 |
| Christopher Kaster | 1 | 5 |
| CHARLES CHON | 1 | 5 |
| D. Keith Grossman | 1 | 5 |
| David Rostov | 1 | 4 |
| Shahzad Malik | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.